Targets › ENG
4 programs from 4 companies in 8 trials: 5 Phase 2, 3 Phase 1; Oncology; next expected readout Apr 2027.
Vascular endothelium glycoprotein that plays an important role in the regulation of angiogenesis. Required for normal structure and integrity of adult vasculature. (UniProt, P17813)
Open in Phaseline: the race on ENG, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University of Washington | CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine Plasmid DNA vaccine encoding multiple tumor-associated antigens (CD105/ENG, Yb-1/YBX1, SOX | ENG, YBX1, SOX2, CDH3, MDM2, CD105, YB1 | Phase 2 | Anatomic Stage IV Breast Cancer AJCC v8; Lung Non-Small Cell Carcinoma; Anatomic Stage IB Breast Cancer AJCC v8; HER2 Negative Breast Carcinoma | Apr 2027 |
| Edwin Posadas, MD | Carotuximab Endoglin inhibitor | ENG | Phase 2 | Castration-resistant Prostate Cancer | Jan 2028 |
| Karen Reckamp, MD, MS | Carotuximab Endoglin inhibitor | ENG | Phase 1 | Non Small Cell Lung Cancer | Jan 2028 |
| West China Hospital | EDS01 Recombinant human endostatin adenovirus vector | ENG | Phase 1 | Head & Neck Cancer | Mar 2028 |
Anatomic Stage IV Breast Cancer AJCC v8 (2) Lung Non-Small Cell Carcinoma (1) Anatomic Stage IB Breast Cancer AJCC v8 (1) HER2 Negative Breast Carcinoma (1) Castration-resistant Prostate Cancer (1) Head & Neck Cancer (1) Non Small Cell Lung Cancer (1)
mixed (3), antibody (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.